Search hospitals > Illinois > Chicago

University of Chicago

Claim this profile
Chicago, Illinois 60637
Global Leader in Skin Cancer
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Breast Cancer
Conducts research for Uterine Tumors
Conducts research for Non-Small Cell Lung Cancer
1389 reported clinical trials
186 medical researchers
Photo of University of Chicago in ChicagoPhoto of University of Chicago in ChicagoPhoto of University of Chicago in Chicago

Summary

University of Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Breast Cancer, Uterine Tumors, Non-Small Cell Lung Cancer and other specialties. University of Chicago is involved with conducting 1,389 clinical trials across 1,693 conditions. There are 186 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Ami V Desai, and Christine M. Bestvina.

Area of expertise

1Skin Cancer
Global Leader
University of Chicago has run 153 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
HER2 positive
2T-Lymphoblastic Leukemia/Lymphoma
Global Leader
University of Chicago has run 143 trials for T-Lymphoblastic Leukemia/Lymphoma. Some of their research focus areas include:
FLT3 positive
BCR-ABL1 positive
HLA-A positive

Top PIs

Clinical Trials running at University of Chicago

Breast Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Coronavirus
Prostate Cancer
Lung Cancer
Multiple Myeloma
Heart Failure
Crohn's Disease
Stroke
Image of trial facility.

Avelumab + Palbociclib/Hydroxychloroquine

for Breast Cancer

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
Recruiting3 awards Phase 212 criteria
Image of trial facility.

Giredestrant + Hormone Therapy

for Early-Stage Breast Cancer

This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Image of trial facility.

Sacituzumab Tirumotecan + Pembrolizumab

for Breast Cancer

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Recruiting2 awards Phase 33 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Chicago?
Where is University of Chicago located?
Who should I call to ask about financial aid or insurance network?
What insurance does University of Chicago accept?
What awards or recognition has University of Chicago received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security